

This is the peer reviewed version of the following article, which has been published in final form at <http://dx.doi.org/10.1111/jsap.12613>.

Verganti, S., Berlato, D., Blackwood, L., Amores-Fuster, I., Polton, G. A., Elders, R., Doyle, R., Taylor, A. and Murphy, S. (2017), Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK. *J Small Anim Pract*, 58: 10–16.

This article may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#).

The full details of the published version of the article are as follows:

TITLE: Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK

AUTHORS: Verganti, S., Berlato, D., Blackwood, L., Amores-Fuster, I., Polton, G. A., Elders, R., Doyle, R., Taylor, A. and Murphy, S.

JOURNAL TITLE: *Journal of Small Animal Practice*

PUBLISHER: Wiley, for British Small Animal Veterinary Association

PUBLICATION DATE: 17 January 2017 (online)

DOI: 10.1111/jsap.12613

# Use of Oncept™ melanoma vaccine in 74 canine oral malignant melanomas in the United Kingdom

S. Verganti<sup>1</sup>, D. Berlato<sup>1</sup>, L. Blackwood<sup>2</sup>, I. Amores-Fuster<sup>2</sup>, G. A. Polton<sup>3</sup>, R. Elders<sup>1</sup>, R. Doyle<sup>4</sup> & A. Taylor<sup>5</sup>, S. Murphy<sup>1</sup>

1. Animal Health Trust, Kentford, Newmarket CB8 7UU
2. School of Veterinary Science, University of Liverpool, Liverpool, Merseyside L3 5DA
3. North Downs Specialist Referrals, Bletchingley, Redhill RH1 4QP
4. Davies Veterinary Specialists, Higham Gobion, Hitchin SG5 3HR
5. The Royal Veterinary College, Kings Cross, London NW1 0TU

Corresponding author email: [sara.verganti@aht.org.uk](mailto:sara.verganti@aht.org.uk)

Keywords – canine, melanoma, oral, treatment, vaccine

1 Summary

2

3 **Objectives** – Oral malignant melanomas (OMM) carry a poor-to-guarded prognosis, due to local  
4 invasiveness and high metastatic propensity. The Oncept™ melanoma vaccine is licensed to treat dogs  
5 with stage II or III locally-controlled OMM. The aim of this retrospective study was to assess survival of  
6 dogs with OMM treated with the vaccine in the UK.

7

8 **Methods** – Medical records of dogs with histopathologically-confirmed OMM that received at least four  
9 doses of the vaccine were evaluated. Survival analyses for potential prognostic factors were performed.

10

11 **Results** – Seventy-four dogs were included. Thirty-seven dogs died of causes attributable to OMM;  
12 median survival time (MST) was 455 days (95% CI, 313-597). Based on Kaplan-Meier survival analysis  
13 with associated log-rank testing, age (<9 years;  $p < 0.001$ ), pigmentation (<50% pigmented cells;  $p = 0.02$ )  
14 and WHO stage ( $p = 0.03$ ) were statistically significant prognostic factors. In a multivariate model, only  
15 age maintained significance ( $p = 0.01$ ). Eight of thirteen patients with macroscopic disease showed clinical  
16 response.

17

18 **Clinical significance** – The patients treated with the melanoma vaccine in our study had MSTs similar to  
19 dogs with OMM receiving the vaccine in the USA. Subpopulations of dogs with significantly varied  
20 responses to the vaccine were identified. Response of patients with macroscopic disease was seen.

21

## 22 **Introduction**

23 Melanoma is the most common malignant tumour of the oral cavity in dogs (Ramos-Vara et al. 2000, Smith  
24 et al. 2002). It usually exhibits aggressive local behaviour and high, early metastatic potential, especially to  
25 regional lymph nodes and lungs (Bostock 1979, Modiano et al. 1999). However, individual tumour behaviour  
26 can vary, as a wide range of survival times has been described (Ottndod et al. 2013). Furthermore, a  
27 proportion of oral tumours are well-differentiated histologically and carry a good prognosis after surgery  
28 alone (Spangler & Kass 2006, Esplin 2008).

29

30 For untreated dogs with oral malignant melanoma (OMM), death due to progressive disease (PD) and/or  
31 metastases occurs after a median time of 2 months (Harvey et al. 1981). Following conventional treatments  
32 [surgery, radiation therapy (RT) and/or chemotherapy], median survival times (MST) range from 4-8 to 12  
33 months (Kosovsky et al. 1991, Wallace et al. 1992, Bateman et al. 1994, Blackwood & Dobson 1996, Théon et  
34 al. 1997, Freeman et al. 2003, Proulx et al. 2003, Murphy et al. 2005, Boston et al. 2014). Surgery and RT are  
35 effective at achieving local tumour control, and curative-intent surgery has recently been associated with  
36 prolonged survival (Tuohy et al. 2014).

37

38 Nevertheless, metastatic disease is a common cause of death for patients with OMM (Blackwood & Dobson  
39 1996, Théon et al. 1997, Murphy et al. 2005). Several studies evaluating the use of conventional  
40 chemotherapy in the adjuvant setting have failed to demonstrate a substantial survival benefit (Rassnick et  
41 al. 2001, Proulx et al. 2003, Murphy et al. 2005, Brockley et al. 2013, Dank et al. 2014).

42

43 Melanoma is a highly immunogenic tumour (Modiano et al. 1999). The Oncept vaccine (Merial, Duluth, GA,  
44 USA) contains plasmid DNA-targeting tyrosinase, a glycoprotein essential for melanin synthesis and  
45 demonstrated to be overexpressed in melanomas (Bergman & Wolchok 2008). Following promising phase I  
46 trial results (Bergman et al. 2003), the vaccine received conditional licensure from the United States  
47 Department of Agriculture in 2007 for treatment of stages II/III, locoregionally controlled canine OMMs. In a  
48 prospective clinical trial of 58 dogs with stage II/III locoregionally controlled OMM, the use of the vaccine  
49 significantly increased survival times compared to historical controls (Grosenbaugh et al. 2011). A  
50 retrospective study failed to demonstrate a survival advantage with the use of the vaccine in a similar  
51 population of dogs (Ottndod et al. 2013). Following USA licensure, the melanoma vaccine has been used in  
52 several UK referral centres to treat dogs with OMM. Recently, a retrospective study of 32 UK-based dogs  
53 with stages I to III OMM treated with the melanoma vaccine showed a MST of 355 days; no prognostic  
54 factors were identified (Treggiari et al. 2016). Nevertheless, the overall data reporting field use remain  
55 sparse. The aims of this retrospective study were to assess survival times of dogs with OMM treated with the

56 melanoma vaccine in UK and to identify possible prognostic factors that might influence survival, and to  
57 describe the use of melanoma vaccine in patients with macroscopic disease.

58

## 59 **Materials and Methods**

### 60 **Animals**

61 Medical records for dogs with OMM that were presented to five UK referral centres from January 2009 to  
62 December 2012 were reviewed (January 2009 is the date the melanoma vaccine became available in the UK).  
63 Inclusion criteria were histological and/or immunohistochemical diagnosis of OMM and dogs that received  
64 the melanoma vaccine as part of the treatment. Dogs diagnosed with well-differentiated oral melanoma or  
65 melanoma involving the haired portion of the lip were excluded from the study because of the more  
66 favourable prognosis associated with these types compared to those of the oral cavity or involving the  
67 mucosal aspect of the lip (Esplin 2008, Smedley et al. 2011). Patients were also excluded if incompletely  
68 staged.

69

70 The following information were collected for each dog: signalment, date of diagnosis, tumour size and site  
71 within the oral cavity, lymph node status, staging performed, completeness of -locoregional control achieved  
72 immediately prior to vaccination [defined as no gross evidence at the excision site and, in cases of metastatic  
73 regional lymph node(s), treatment of the lymph node(s) with surgery or RT prior to vaccination]. The initial  
74 vaccination dates, number of vaccine doses, adverse effects, and other treatments apart from the vaccine  
75 were also recorded. The following information was retrieved from the histopathology reports: percentage of  
76 pigmented neoplastic cells, mitotic index (MI) and extent of surgical margins. Surgical margins were  
77 considered complete if the narrowest histologic margin was >2 mm. Dogs were staged according to the  
78 World Health Organisation tumour, node, metastases (TNM) guidelines (Table 1). For dogs with macroscopic  
79 disease, response was retrospectively assessed according to the response evaluation criteria in solid tumours  
80 (RECIST) (Nguyen et al. 2015). The vaccine was administered using the Vetjet transdermal device according  
81 to the manufacturer's instructions as previously described (Grosenbaugh et al. 2011). The "induction course"  
82 consisted of four doses 14 days apart; a booster vaccination was administered approximately every six  
83 months. Minor variations in vaccination schedule occurred to meet clients' needs. Information regarding  
84 cause of death and presence/absence of macroscopic or metastatic disease for patients alive at the end of  
85 the study were assessed clinically and/or via diagnostic imaging by either the primary or referral clinician and  
86 collected when available.

87

### 88 **Data analysis**

89 The primary outcome measures were overall survival (OS), defined as the time from date of surgery until

90 date of death or euthanasia, and disease-free interval (DFI), defined as the time from surgery to recurrence  
91 or development of metastatic disease or death. An event was defined as death or euthanasia attributed to  
92 OMM. Dogs were classified as censored if they died or were euthanased due to unrelated causes, were alive  
93 at the end of the study or were lost to follow-up. Variables examined to determine their effect on OS  
94 included MI [ $<4/10$  high powered fields (hpfs) vs  $\geq 4/10$  hpfs], percentage of pigmentation by histopathology  
95 ( $<50\%$  pigmented neoplastic cells vs  $\geq 50\%$ ), margins of excision (complete vs incomplete), WHO stage and  
96 regional lymph node status (metastatic vs non-metastatic). Lymph nodes that were normal in size but not  
97 sampled were considered non-metastatic in the statistical analysis. Kaplan-Meier product-limit estimation  
98 was used to estimate OS plots for potential categorical risk factors, and log-rank testing was used to compare  
99 survival impact of categorical variables. Values of  $P < 0.05$  were considered significant. Statistical analysis was  
100 performed using commercial software (IBM SPSS Statistics version 20.0). Statistical analysis was performed  
101 for patients with locoregional control prior to vaccination (stages I to III), while dogs with macroscopic  
102 disease were considered separately. Due to the low number of patients in the latter group, Kaplan-Meier  
103 product-limit estimation was used to estimate only OS plot.

104

## 105 **Results**

106 Sixty-nine dogs met the inclusion criteria; 56 patients had locoregional tumour control prior to vaccination  
107 while 13 dogs had macroscopic disease. The median age for the entire population was 10.9 years (range 5.2  
108 to 15.4 years). Patient signalment, clinical stage, treatments received and achievement of locoregional  
109 tumour control prior to vaccine are shown in Table 2. Histopathology reports were available for review in 67  
110 cases. Fifty-nine tumours (88.1%) had MI  $\geq 4/10$  hpfs (median 35.0/10 hpfs, range 4 to 150/10 hpfs) and 24  
111 (35.8%) had  $<50\%$  pigmented cells. Table 3 indicates details of the RT protocols and chemotherapy  
112 treatments administered.

113 In 13 cases the melanoma vaccine was used in the presence of macroscopic disease. Eight dogs had tumour  
114 recurrence after surgery ( $\pm$ RT), and concurrent regional lymph node involvement was found in three of  
115 these. Three of these eight patients concurrently received non-steroidal anti-inflammatory drugs (NSAIDs)  
116 and one received RT. Of the remaining dogs, the vaccine was used as palliative treatment for distant gross  
117 metastatic disease (three cases) and for the primary tumour after incisional biopsy (one case). In one dog the  
118 vaccine was initiated prior to surgery. Patients in the macroscopic group were staged as follows: four for  
119 stage I and three each for stages II to IV.

120

121 Three hundred and seven doses of the melanoma vaccine were administered (mean 4.5, median 4)  
122 beginning at a median of 42 days after diagnosis (range 4 to 409 days). Most dogs (76.8%) received four  
123 doses of the vaccine; 16 (23.2%) dogs had one to five booster vaccinations (mean 1.9, median 1). All patients  
124 completed the induction course of the vaccine. However, one dog in the macroscopic group had PD after  
125 starting the vaccine, at which point surgery was performed. The vaccine was restarted after surgery and the  
126 treatment was completed. Adverse effects suspected to be related to the vaccine were reported in 12 dogs

127 (17.4%) and included: pain at injection site (4), lethargy (2), local erythema (2), focal hair discolouration (2)  
128 and one each of lethargy and anorexia, subcutaneous haemorrhage at injection site and restlessness. Most  
129 of the adverse effects were temporary (<48 hours) and reported after the first or second vaccination; none  
130 were described following boosters. Additionally, one dog developed a squamous cell carcinoma (SCC) at the  
131 vaccination site.

## 132 Outcomes

133 At the time of analysis, 50% (28/56) of dogs with stages I to III OMM had died or were euthanased for causes  
134 attributable to OMM: 10 (17.9%) because of local recurrence at the surgical or RT site (five had concurrent  
135 involvement of the regional lymph node) and 16 (28.6%) due to metastasis (including regional lymph nodes,  
136 lungs, liver, brain, tonsil and skin), and two of unknown causes (but assumed to be melanoma-related by  
137 clinical determination). The MST for dogs staged I to III was 455 days (95% CI: 324 to 586 days; Fig 1) and the  
138 median DFI was 222 days (95% CI: 175 to 269 days; Fig 2). The MST from start of vaccination was 422 days  
139 (95% CI: 255 to 589 days).

140 Eight dogs (14.3%) staged I to III survived less than 6 months; 62.5% of these had <50% pigmented neoplastic  
141 cells. Eleven dogs (19.6%) experienced long-term survival (615 to 1070 days), six of which were still alive at  
142 the end of the study. Of these 11 patients, eight had a melanotic tumour and three amelanotic. In eight dogs  
143 complete margins were achieved. Three of the eleven long-term survivors had stage I disease, five stage II  
144 and three stage III at initial presentation; six had surgery before the vaccine, four had surgery + RT (three  
145 before and one after the induction course of the vaccine) and one surgery + chemotherapy.

146 In the censored group, 22 dogs (39.3%) were alive and 18 were free of detectable disease (11 cases based on  
147 clinical examination; for the other seven patients, diagnostic imaging confirmed remission). Of the remaining  
148 four dogs, three had documented local recurrence (in two patients there was also regional lymph node  
149 involvement) and one dog had suspected pulmonary metastases by CT. Of the 18 dogs considered disease-  
150 free, nine staged I, four staged II and five staged III at initial presentation. Median follow-up time for  
151 censored dogs was 300 days (range 72 to 1070 days). One dog was lost to follow-up 615 days after initial  
152 diagnosis and considered free of detectable disease based on diagnostic imaging findings. Six dogs died or  
153 were euthanased due to causes other than OMM (10.7%), including second malignancy (multi-centric  
154 lymphoma, osteosarcoma, haemangiosarcoma), gastric dilation/volvulus, pulmonary-thromboembolism and  
155 hyperadrenocorticism.

156 A Kaplan-Meier survival plot and associated log-rank test suggested that MI (P=0.47), degree of  
157 pigmentation (P=0.09), margins (P=0.27), WHO stage (P=0.19) and lymph node status (P=0.68) were not  
158 statistically-significant prognostic factors.

159 Of the 13 patients with macroscopic disease at the time of first vaccination, three dogs achieved complete  
160 response (CR) of the primary tumour during the vaccine induction course. Two of these patients did not  
161 receive any other treatment and developed local recurrence 125 days and 139 days after the first  
162 vaccination; the third dog received firocoxib and had no evidence of local recurrence based on clinical  
163 examination 232 days after the first vaccination. One patient with local disease and involvement of the  
164 regional lymph node prior to vaccine had a partial response (PR) during the induction course but CR was  
165 described at the time of the first booster vaccination; this dog was receiving meloxicam and was alive and  
166 considered disease-free based on clinical examination 232 days after the first vaccination. A PR was seen in  
167 another dog though the tumour was also treated with RT at the same time. Of three dogs with stable disease

168 (SD), one was receiving meloxicam and had PD after 164 days; the other two were treated with the vaccine  
169 only and the disease considered stable at last follow-up. The rest of the patients, including all stage IV  
170 melanomas, had PD. The MST for patients in the macroscopic group was 179 days from diagnosis (95% CI: 95  
171 to 263 days; Fig 3). The three patients with stage IV melanoma survived 171, 178 and 288 days from  
172 diagnosis, and 129, 130 and 241 days from the vaccination. None of these patients received other type of  
173 treatments, apart from surgery and melanoma vaccine.

## 174 Discussion

175 The purpose of this study was to retrospectively evaluate the survival times of dogs with OMM in the UK  
176 treated with the melanoma vaccine and to possibly identify associated prognostic factors for response. An  
177 additional aim was to describe the response of patients with macroscopic disease to the vaccine.

178 The Oncept vaccine has been used to treat canine melanoma in UK referral centres after acquiring  
179 conditional FDA licensing in 2007 but publications evaluating effectiveness are limited. Furthermore, the two  
180 largest studies assessing the vaccine efficacy reported contrasting results (Grosenbaugh et al. 2011, Ottnod  
181 et al. 2013). The overall MST described in our study (455 days) for patients with stages I to III disease, was  
182 similar to that described by Ottnod et al. (2013) in which MST for vaccinated dogs was 477 vs 491 days for  
183 historical "controls". However, our study included 14 patients (25%) with stage I disease which may have  
184 positively impacted survival compared to studies in which the vaccine was used for stages II and III OMMs  
185 only. Conversely, if we compare our data to those from a recent UK study including stages I to III (Treggiari et  
186 al. 2016), improved survival was achieved in this study.

187 The degree of pigmentation of canine melanoma has been associated with survival in some studies (Esplin  
188 2008, Bergin et al. 2011); however, others have failed to demonstrate any correlation (Harvey et al. 1981,  
189 Hahn et al. 1994, Ramos-Vara et al. 2000). Although not statistically significant in our study population the  
190 MST for tumours with  $\geq 50\%$  pigmented neoplastic cells was 508 days compared to 310 days for tumours  
191 with  $< 50\%$  pigmented neoplastic cells. Our results support the idea that less pigmented tumours might be  
192 clinically more aggressive but this notion requires further formal testing in larger case series.

193 In our population of dogs with stages I to III OMM, complete surgical margins were achieved in 13 patients  
194 (23.2%). Only 19 dogs (44.1%) with incomplete margins received adjuvant radiation therapy. Completeness  
195 of excision was not a statistically significant prognostic factor in our study. This is similar to results described  
196 by Grosenbaugh et al. (2011) and Ottnod et al. (2013), in which margins of excision did not correlate with  
197 survival. Nevertheless, for our patients with complete margins the MST was not reached and the mean  
198 survival was 628 days (95% CI: 388 to 869 days) compared to a MST of 417 days [95% CI: 266 to 568 days;  
199 mean 477 days (95% CI: 378 to 575 days)] for patients with incomplete margins. The lack of significance seen  
200 in this study could again be due to type II error or to the lack of histopathology review for confirmation of  
201 the margins of excision.

202 In our study, WHO stage was not statistically significantly associated with survival ( $P=0.19$ ). However, for  
203 patients with stage I disease the MST was not reached while the mean survival was 687 days (95% CI: 462 to  
204 912 days). Interestingly, dogs with stage II disease had a shorter MST compared to patients with stage III  
205 disease [269 days (95% CI: 118 to 421 days) and 342 days (95% CI: 214 to 470 days), respectively]. Several  
206 factors could have contributed to this. For example, 10/22 dogs with stage II disease had amelanotic  
207 tumours (45.4%) vs 5/20 (25%) patients with stage III disease. Furthermore, complete margins were  
208 achieved in 20% of staged III patients vs 9% of the dogs with staged II tumours. In regards to other treatment

209 modalities (e.g. RT and chemotherapy) and time of delayed vaccination, these were similar for both groups.  
210 If we compare our results to the recent UK study on the melanoma vaccine (Treggiari et al. 2016), our stage  
211 II population experienced shorter survival while dogs with stages I and III disease had increased survival.  
212 Both studies are retrospective in nature and several confounding factors may have contributed to these  
213 results. Additionally, the dogs in this study received a combination of treatment modalities including surgery,  
214 RT, chemotherapy and NSAIDs. Based on the small number of patients for each subgroup, no statistical  
215 analysis was performed to assess the influence of different treatments on survival. However, it is not  
216 possible to exclude the potential role of chemotherapy and NSAIDs on tumour control. COX-2 expression has  
217 in fact been demonstrated in canine melanoma tissue, particularly in aggressive OMMs (Pires et al. 2010).  
218 Nevertheless, two previous studies (Boria et al. 2004, Murphy et al. 2005) showed that the use of NSAIDs for  
219 canine melanomas did not confer a biological response or survival advantage.

220 Interestingly, in our study, 50% of patients with stages I to III disease died due to local recurrence (with or  
221 without regional lymph node involvement; 17.9%) or due to metastatic disease (29.6%); lymph nodes, lungs,  
222 liver, brain, tonsil and skin, were the described metastatic sites. This suggests that the melanoma vaccine  
223 may not be effective in all the patients treated or that its effect may be temporary.

224 Eleven dogs (19.6%) staged I to III experienced long-term survival (615 to 1070 days), six of which were still  
225 alive at the end of the study. Several factors may have contributed to this result, including the presence of  
226 pigmented tumours in eight patients as well the achievement of complete margins for most of them (72.7%).

227 As previously described by Hahn et al. (1994) and Proulx et al. (2003), regional lymph node metastasis did  
228 not appear to impact survival in our study population. However, seven patients with palpably normal lymph  
229 nodes did not have lymph node sampling performed at initial staging. This may have underestimated the  
230 number of cases with regional lymph node involvement, as up to 40% of normal lymph nodes are metastatic  
231 (Williams & Packer 2003). Nevertheless, none of the patients developed detectable lymph node metastases  
232 during the study period.

233 The time between diagnosis and vaccination was extremely variable in our study (4 to 409 days). This was  
234 due to the fact that the melanoma vaccine was not available in the UK before 2009. The median time of first  
235 vaccination was 43 days after surgery (range 4 to 364 days) for patients with stages I to III disease, and 33  
236 days (range 11 to 409 days) for dogs in the macroscopic group. Most of the dogs with stages I to III tumours  
237 (71.4%) received the first dose of the melanoma vaccine within 2 months from diagnosis. Although there are  
238 no clear guidelines about when to start the vaccine, an early vaccination is recommended in order to give  
239 time to mount an immune response. Therefore, the delayed vaccination may have negatively influenced the  
240 outcome of some of our patients. Nevertheless, patients that received the vaccine at later stage may have  
241 also had less aggressive tumours. No statistical analysis was performed as to whether delayed vaccination  
242 was a significant prognostic factor in our population; however, the MSTs of stages I to III patients from  
243 diagnosis and vaccination were similar (455 days and 422 days, respectively).

244 The melanoma vaccine was well-tolerated. Minimal adverse effects were described by owners, most being  
245 mild and self-limiting; the frequency of adverse reactions declined throughout the vaccination course. One  
246 dog developed SCC in the area of the vaccination site nine months after the first vaccine diagnosed using  
247 cytology. It is unclear whether this was related to the vaccine.

248

249 The effect of the vaccine on macroscopic disease was described for the first time in this paper. Overall, eight  
250 of 13 patients showed clinical response. However, four of these patients had received other forms of  
251 treatment concurrent with the vaccine, including RT (one) and NSAIDs (three dogs). The overall response  
252 rate of the nine patients with macroscopic disease treated with the vaccine only was 44.4%. Of the four  
253 responders, two had CR and two had SD. It is interesting that in three dogs, response was documented  
254 during the induction course of the vaccine. The early response seen in this study was unexpected as a  
255 humoral response is reportedly detected within three to nine months after completion of the induction  
256 course of the melanoma vaccine (Liao et al. 2006). In our population it seems that some patients were able  
257 to develop a much more rapid response. Nevertheless, in most cases, the response was short-lasting (<4.5  
258 months).

259 Three patients with stage IV disease treated with surgery and vaccine only survived between 5.6 and 9.5  
260 months from the initial diagnosis. Although these patients developed eventually -progressive disease, it is  
261 not possible to exclude that the vaccine had a potential role in slowing disease progression. Based on this  
262 preliminary data and the tolerability of the treatment, the melanoma vaccine could be considered as  
263 palliative treatment in patients with macroscopic disease, when surgery or radiotherapy is not an option, or  
264 for patients with advanced disease (i.e. stage IV). However, the response seen was extremely variable and  
265 further studies are required to investigate the role of the vaccine in the macroscopic setting.

266 Due to its retrospective nature, there are several limitations in this study. Necropsy was not performed in  
267 any dogs; the attributed cause of death was often based on clinical examination by the referring or referral  
268 veterinarian and standard diagnostic procedures. Histopathology records were not available for two dogs  
269 and tumour samples were not reviewed, so variation between pathologists regarding histologic features of  
270 malignancy might exist. There was no control group, which limited the possibility of assessing the effect of  
271 the vaccine on survival. Additionally, the limited number of dogs in some subcategories might have  
272 introduced bias. Finally, cases were managed by multiple investigators and treatment type and time of  
273 vaccine initiation varied.

274 In conclusion, our study dogs with OMM treated with the Oncept melanoma vaccine showed similar MSTs to  
275 those reported by Ottnod et al. (2013). In addition, our stage III patients had improved survival compared to  
276 a recent UK study on dogs treated with the vaccine (Treggiari et al. 2016). However, considering the  
277 limitations of this study, the lack of a control group and the different treatment modalities used for each  
278 patient, it is not clear whether the vaccine resulted in a survival advantage in our population. None of the  
279 prognostic factors analysed in the present study was statistically significant. Although this could be a genuine  
280 result, it is not possible to exclude type II error, based on the low number of patients in each subcategory  
281 and on the limitations of a retrospective study.

282 Nevertheless, this is the first study that describes the use of the vaccine in dogs with macroscopic disease.  
283 Patients with macroscopic disease had a 44.4% response rate to the vaccine and the MST for dogs with stage  
284 IV disease was 178 days. Therefore, given its very good tolerability, the melanoma vaccine may be  
285 considered as palliative treatment for patients with advanced disease (e.g. stage IV) or for dogs with  
286 macroscopic tumours when other treatment modalities are not an option.

287

288 **References**

- 289 Bateman, K. E., Catton, P. A., Pennock, P. W., et al. (1994) 0-7-21 Radiation therapy for the treatment of  
290 canine oral melanoma. *Journal of Veterinary Internal Medicine* **8**, 267-272  
291
- 292 Bergin, I. L., Smedley, R. C., Esplin, D. G., et al. (2011) Prognostic evaluation of Ki67 threshold value in  
293 canine oral melanoma. *Veterinary Pathology* **48**, 41-53  
294
- 295 Bergman, P. J. & Wolchok, J. D. (2008) Of mice and men (and dogs): development of a xenogeneic DNA  
296 vaccine for canine oral malignant melanoma. *Cancer Therapy* **6**, 817-826  
297
- 298 Bergman, P. J., McKnight, J., Novosad, A., et al. (2003) Long-term survival of dogs with advanced  
299 malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. *Clinical*  
300 *Cancer Research* **9**, 1284-1290  
301
- 302 Blackwood, L. & Dobson, J. M. (1996) Radiotherapy of oral malignant melanomas in dogs. *Journal of the*  
303 *American Veterinary Medical Association* **209**, 98-102  
304
- 305 Boria, P. A., Murry, D. J., Bennett, P. F., et al. (2004) Evaluation of cisplatin combined with piroxicam for  
306 the treatment of oral malignant melanoma and oral squamous cell carcinomas in dogs. *Journal of the*  
307 *American Veterinary Medical Association* **224**, 388-394  
308
- 309 Bostock, D. E. (1979) Prognosis after surgical excision of canine melanomas. *Veterinary*  
310 *Pathology* **16**, 32-40  
311
- 312 Boston, S. E., Lu, X., Culp, W. T. N., et al. (2014) Efficacy of systemic adjuvant therapies administered to  
313 dogs after excision of oral malignant melanomas: 151 cases (2001-2012). *Journal of the American*  
314 *Veterinary Medical Association* **245**, 401-407  
315
- 316 Brockley, L. K., Cooper, M. A. & Bennett, P. F. (2013) Malignant melanoma in 63 dogs (2001-2011): the  
317 effect of carboplatin chemotherapy on survival. *New Zealand Veterinary Journal* **61**, 25-31  
318
- 319 Dank, G., Rassnick, K. M., Sokolovsky, Y., et al. (2014) Use of adjuvant carboplatin for treatment of dogs  
320 with oral malignant melanoma following surgical excision. *Veterinary and Comparative Oncology* **12**, 78-  
321 84  
322
- 323 Esplin, D. G. (2008) Survival of dogs following surgical excision of histologically well-differentiated  
324 melanocytic neoplasms of the mucous membranes of the lips and oral cavity. *Veterinary*  
325 *Pathology* **45**, 889-896  
326
- 327 Freeman, K. P., Hahn, K. A., Harris, F. D., et al. (2003) Treatment of dogs with oral melanoma by  
328 hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). *Journal of Veterinary*  
329 *Internal Medicine* **17**, 96-101  
330
- 331 Grosenbaugh, D. A., Leard, T., Bergman, P. J., et al. (2011) Safety and efficacy of a xenogeneic DNA  
332 vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs  
333 following surgical excision of the primary tumor. *American Journal of Veterinary Research* **72**, 1631-1638  
334
- 335 Hahn, K. A., DeNicola, D. B., Richardson, R. C., et al. (1994) Canine oral malignant melanoma:  
336 prognostic utility of an alternative staging system. *Journal of Small Animal Practice* **35**, 251-256  
337
- 338 Harvey, H. J., MacEwen, E. G., Braun, D., et al. (1981) Prognostic criteria for dogs with oral  
339 melanoma. *Journal of the American Veterinary Medical Association* **178**, 580-582  
340
- 341 Kosovsky, J. K., Matthiesen, D. T., Marretta, S. M., et al. (1991) Results of partial mandibulectomy for  
342 the treatment of oral tumors in 142 dogs. *Veterinary Surgery* **20**, 397-401

343 Liao, J. C., Gregor, P., Wolchok, J. D., et al. (2006) Vaccination with human tyrosinase DNA induces  
344 antibody responses in dogs with advanced melanoma. *Cancer Immunity* **21**, 6-8  
345

346 Modiano, J. F., Ritt, M. G. & Wojcieszyn, J. (1999) The molecular basis of canine melanoma:  
347 pathogenesis and trends in diagnosis and therapy. *Journal of Veterinary Internal Medicine* **13**, 163-174  
348

349 Murphy, S., Hayes, A. M., Blackwood, L., et al. (2005) Oral malignant melanoma – the effect of coarse  
350 fractionation radiotherapy alone or with adjuvant carboplatin therapy. *Veterinary and Comparative*  
351 *Oncology* **3**, 222-229  
352

353 Nguyen, S. M., Thamm, D. H., Vail, D. M., et al. (2015) Response evaluation criteria for solid tumours in  
354 dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. *Veterinary and*  
355 *Comparative Oncology* **13**, 176-183  
356

357 Otnod, J. M., Smedley, R. C., Walshaw, R., et al. (2013) A retrospective analysis of the efficacy of  
358 Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. *Veterinary and*  
359 *Comparative Oncology* **11**, 219-229  
360

361 Pires, I., Garcia, A., Prada, J., et al. (2010) COX-1 and COX-2 expression in canine cutaneous, oral and  
362 ocular melanocytic tumours. *Journal of Comparative Pathology* **143**, 142-149  
363

364 Proulx, D. R., Ruslander, D. M., Dodge, R. K., et al. (2003) A retrospective analysis of 140 dogs with oral  
365 melanoma treated with external beam radiation. *Veterinary Radiology & Ultrasound* **44**, 352-359  
366

367 Ramos-Vara, J. A., Beissenherz, M. E., Miller, M. A., et al. (2000) Retrospective study of 338 canine oral  
368 melanomas with clinical, histologic, and immunohistochemical review of 129 cases. *Veterinary*  
369 *Pathology* **37**, 597-608  
370

371 Rassnick, K. M., Ruslander, D. M., Cotter, S. M., et al. (2001) Use of carboplatin for treatment of dogs  
372 with malignant melanoma: 27 cases (1989-2000). *Journal of the American Veterinary Medical*  
373 *Association* **218**, 1444-1448  
374

375 Smedley, R. C., Spangler, W. L., Esplin, D. G., et al. (2011) Prognostic markers for canine melanocytic  
376 neoplasms: a comparative review of the literature and goals for future investigation. *Veterinary*  
377 *Pathology* **48**, 54-72  
378

379 Smith, S. H., Goldschmidt, M. H. & McManus, P. M. (2002) A comparative review of melanocytic  
380 neoplasms. *Veterinary Pathology* **39**, 651-678  
381

382 Spangler, W. L. & Kass, P. H. (2006) The histologic and epidemiologic bases for prognostic  
383 considerations in canine melanocytic neoplasia. *Veterinary Pathology* **43**, 136-149  
384

385 Théon, A. P., Rodriguez, C. & Madewell, B. R. (1997) Analysis of prognostic factors and patterns of  
386 failure in dogs with malignant oral tumors treated with megavoltage irradiation. *Journal of the American*  
387 *Veterinary Medical Association* **210**, 778-784  
388

389 Treggiari, E., Grant, J. P. & North, S. M. (2016) A retrospective review of outcome and survival following  
390 surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. *Journal of*  
391 *Veterinary Medical Science* **78**, 845-850  
392

393 Tuohy, J. L., Selmic, L. E., Worley, D. R., et al. (2014) Outcome following curative-intent surgery for oral  
394 melanoma in dogs: 70 cases (1998-2011). *Journal of the American Veterinary Medical*  
395 *Association* **245**, 1266-1273  
396

397 Wallace, J., Matthiesen, D. T. & Patnaik, A. K. (1992) Hemimaxillectomy for the treatment of oral tumors  
398 in 69 dogs. *Veterinary Surgery* **21**, 337-341

399 Williams, L. E. & Packer, R. A. (2003) Association between lymph node size and metastases in dogs  
400 with oral malignant melanoma: 100 cases (1987-2001). *Journal of the American Veterinary Medical*  
401 *Association* **222**, 1234-1236  
402

403 **Table 1.** World Health Organisation staging system for dogs with OMM

Clinical stage
<p>I. Tumour &lt; 2 cm diameter            II. Tumour 2-4 cm diameter            III. Tumour &gt; 4 cm diameter and/or evidence of regional lymph node involvement            IV. Any tumour size, any lymph node status, evidence of distant metastasis</p>

404

405 **Table 2.** Characteristics of the 69 dogs with OMM treated with the melanoma vaccine

Category	Variable	n (%)
Breed	Purebreed	51 (68.9%)
	Golden retriever	16 (21.6%)
	Labrador retriever	6 (8.1%)
	Flat-coated retriever	1 (1.4%)
	Mixed breed	23 (31.1%)
Gender	Male	53 (71.6%)
	Neutered	34 (46%)
	Entire	19 (25.7%)
	Female	21 (28.4%)
	Spayed	18 (24.3%)
Entire	3 (4%)	
Location	Gingival	
	Maxillary	24 (32.4%)
	Mandibular	19 (25.7%)
	Labial (mucosal aspect)	21 (28.4%)
	Lingual	5 (6.8%)
	Hard palatal	3 (4%)
Oropharyngeal	2 (2.7%)	
Investigations performed	Physical examination	74 (100%)
	Blood tests	63 (85.1%)
	Thoracic radiography	55 (74.3%)
	CT scan	
	Thorax	34 (45.9%)
	Abdomen	16 (21.6%)
	Abdominal ultrasonography	18 (24.3%)
	Regional lymph node assessment	62 (83.8%)
	Cytology	55 (88.7%)
Histopathology	13 (21%)	
Clinical stage	I II	18 (24.3%)
	III	24 (32.4%)
	IV	23 (31.1%)
	Unknown	3 (4%)
		6 (8.1%)

Treatment modality	Surgery	74 (100%)
	Complete margins	18 (24.3%)
	Incomplete margins	56 (75.4%)
	Radiation therapy	24 (32.4%)
	Primary site	6 (8.1%)
	Primary site and local lymph nodes	18 (24.3%)
	Systemic treatment	28 (37.8%)
	NSAIDs	18 (24.3%)
	Chemotherapy	11 (14.9%)
Toceranib phosphate	2 (2.7%)	
Local tumour control prior to vaccine	Yes	61 (82.4%)
	No	13 (17.6%)
	Residual primary mass	7 (9.5%)
	Regional lymph nodes	6 (8.1%)
	Lungs	3 (4.1%)

415

416


417 **Table 3.** Radiation therapy protocols and chemotherapy treatments for the 69 patients with OMM

Radiation therapy	n (%)	Chemotherapy/TKI treatment	n (%)
Patients treated	24 (32.4%)	Patients treated	13 (17.6%)
Type of treatment		Type of treatment	
Adjuvant to surgery	20 (27.0%)	Adjuvant to surgery and/or RT	6 (8.1%)
Main treatment	2 (2.7%)	At local recurrence	7 (9.5%)
At local recurrence	2 (2.7%)		
In relation to melanoma vaccine		In relation to melanoma vaccine	
Pre-vaccine	12 (16.2%)	Pre-vaccine	6 (8.1%)
Concurrent to vaccine	10 (13.5%)	Concurrent to vaccine	4 (5.4%)
Post-vaccine	2 (2.7%)	Post-vaccine	11 (14.9%)
Protocol		Protocol	
4 fractions x 8 Gy	18 (24.3%)	Carboplatin	5 (6.8%)
4 fractions x 8.5 Gy	1 (1.4%)	Carboplatin and mitoxantrone	1 (1.4%)
4 fractions x 9 Gy	5 (6.8%)	Metronomic chlorambucil/NSAIDs	3 (4.0%)
Treatment of regional lymph node	18 (24.3%)	Metronomic CXP/NSAIDs	4 (5.4%)
Prophylactic	13 (17.6%)	Toceranib phosphate	2 (2.7%)
Metastatic lymph node/s	5 (6.8%)		

418


419

420 **Figure 1.** Kaplan-Meier plot showing the median survival time of the 56 patients with locoregional control  
421 prior to vaccination (stages I to III). The overall median survival time was 455 days (95% CI, 324 to 586 days).  
422 Crosses represent censored observations.




423  
424  
425

426 **Figure 2.** Kaplan-Meier plot showing the disease-free interval of the 56 patients with locoregional control  
427 prior to vaccination (stages I to III). The overall disease-free interval was 222 days (95% CI, 175 to 269 days).  
428 Crosses represent censored observations.



429  
430

431 **Figure 3.** Kaplan-Meier plot showing the median survival time of the 13 patients with macroscopic disease  
432 prior to vaccination. The overall median survival time was 178 days (95% CI, 95 to 263 days). Crosses  
433 represent censored observations.



434